Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.
Stada has outlined plans to become a “major pharma player in Ukraine” by acquiring the prescription and consumer health businesses of local firm Biopharma, “one of the key pharmaceutical producers” in the country.
The deal – financial details of which were not disclosed, outside of Stada’s assertion that it represented “one of the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
